Calcium Channel Antagonists (Migraine) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 42 Pages
|作為鈣離子阻斷劑(用作偏頭痛治療藥):市場預測與分析 Calcium Channel Antagonists (Migraine) - Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 42 Pages||
鈣離子阻斷劑當初由於具有擴張腦血管結構上血管的效果，而成為眾所關注的偏頭痛治療法(Montastruc and Senard, 1992)。但其效果大半是藉由介入緩慢的膜電位依賴性通道，以阻斷跨膜內流的鈣離子通過。鈣離子通道依細胞內部、外部不同位置而分為不同種類──電壓門控性鈣離子通道(依電壓高低開啟關閉)、配體門控性鈣離子通道(依化學傳達物質開啟關閉)。
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Calcium channel antagonists initially evoked interest in the treatment of migraine due to their vasodilator effects on the cerebral vasculature (Montastruc and Senard, 1992). However, their effects are most likely due to blocking the transmembrane influx of calcium across cell membranes through slow, voltage-dependent channels. Calcium channels are located extracellularly or intracellularly and consist of different subtypes: those that are voltage-gated (opened by depolarization) and ligand-gated (opened by chemical messengers).